$1.69
−0.29%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.74
From 52W high−69.16%
Volume438843.00
Market cap$134.66M
P/E (TTM)—
P/S (TTM)90.0x
Div yield—
Key dataOct 19, 2026
Open
$1.74
From 52W high
−69.16%
Volume
438843.00
Market cap
$134.66M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
P/E (TTM)
—
RSI (14)
32.5
MomentumView details →
1D Return
−0.29%
YTD Return
−44.06%
SummaryUpdated Jun 1, 2026
Tharimmune, Inc. (NASDAQ:THAR) is a clinical-stage biotechnology company founded in 2017 and headquartered in Bridgewater, New Jersey. The company was originally incorporated as Hillstream BioPharma, Inc. before changing its name to Tharimmune in September 2023. Since going public in January 2022, Tharimmune has focused on developing therapeutic candidates targeting rare diseases, inflammatory conditions, and various forms of cancer. The company operates in the highly specialized and capital-intensive biotechnology sector, where drug development timelines typically span many years and require substantial investment before generating any revenue.
Similar companies
Latest newsMore news →
Canton Strategic Holdings announced it will host a publicly available webinar to discuss its ecosystem report on October 21, 2026 at 11:00 a.m.5d agoAir France-KLM and Lufthansa Group submitted final improved binding bids to Portugal's Parpública for a 44.9% minority stake in state-owned TAP Air Portugal, valuing the carrier at over €2bn.15d ago